AR040350A1 - Inhibidores de caspasa y usos de los mismos - Google Patents
Inhibidores de caspasa y usos de los mismosInfo
- Publication number
- AR040350A1 AR040350A1 ARP030102352A ARP030102352A AR040350A1 AR 040350 A1 AR040350 A1 AR 040350A1 AR P030102352 A ARP030102352 A AR P030102352A AR P030102352 A ARP030102352 A AR P030102352A AR 040350 A1 AR040350 A1 AR 040350A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- halo
- straight
- ocf3
- branched
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 201000010099 disease Diseases 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 230000006378 damage Effects 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 230000001105 regulatory effect Effects 0.000 abstract 3
- 208000020084 Bone disease Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 208000034578 Multiple myelomas Diseases 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003645 Atopy Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract 1
- 241000543381 Cliftonia monophylla Species 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000001490 Dengue Diseases 0.000 abstract 1
- 206010012310 Dengue fever Diseases 0.000 abstract 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000003807 Graves Disease Diseases 0.000 abstract 1
- 208000015023 Graves' disease Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 abstract 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 206010019773 Hepatitis G Diseases 0.000 abstract 1
- 206010019755 Hepatitis chronic active Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 201000005807 Japanese encephalitis Diseases 0.000 abstract 1
- 241000710842 Japanese encephalitis virus Species 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 208000027747 Kennedy disease Diseases 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010053159 Organ failure Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000024777 Prion disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010043781 Thyroiditis chronic Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 abstract 1
- 208000003152 Yellow Fever Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 150000001414 amino alcohols Chemical class 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000005000 autoimmune gastritis Diseases 0.000 abstract 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 208000025729 dengue disease Diseases 0.000 abstract 1
- 230000001066 destructive effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000000718 duodenal ulcer Diseases 0.000 abstract 1
- 206010014599 encephalitis Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000021039 metastatic melanoma Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 206010034674 peritonitis Diseases 0.000 abstract 1
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000002320 spinal muscular atrophy Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 206010043554 thrombocytopenia Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39259202P | 2002-06-28 | 2002-06-28 | |
| US43507302P | 2002-12-20 | 2002-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040350A1 true AR040350A1 (es) | 2005-03-30 |
Family
ID=30003264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102352A AR040350A1 (es) | 2002-06-28 | 2003-06-27 | Inhibidores de caspasa y usos de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7553852B2 (enExample) |
| EP (1) | EP1539701A1 (enExample) |
| JP (2) | JP4616643B2 (enExample) |
| KR (1) | KR20050013260A (enExample) |
| CN (1) | CN100503572C (enExample) |
| AR (1) | AR040350A1 (enExample) |
| AU (1) | AU2003248758A1 (enExample) |
| BR (1) | BR0312232A (enExample) |
| CA (1) | CA2493646A1 (enExample) |
| IL (1) | IL165986A0 (enExample) |
| MX (1) | MXPA05000069A (enExample) |
| NO (1) | NO20050851L (enExample) |
| NZ (1) | NZ537807A (enExample) |
| PE (1) | PE20040728A1 (enExample) |
| PL (1) | PL374598A1 (enExample) |
| RU (1) | RU2005102094A (enExample) |
| TW (1) | TW200404783A (enExample) |
| UY (1) | UY27872A1 (enExample) |
| WO (1) | WO2004002961A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| MXPA05000069A (es) | 2002-06-28 | 2005-04-11 | Vertex Pharma | Inhibidores de caspasa y uso de los mismos. |
| US7612091B2 (en) | 2002-12-20 | 2009-11-03 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| AU2005249503B2 (en) | 2003-11-10 | 2011-08-25 | Vertex Pharmaceuticals Incorporated | ICE inhibitors for the treatment of autoinflammatory diseases |
| SI2399915T1 (sl) | 2004-03-12 | 2015-05-29 | Vertex Pharmaceuticals Incorporated | Postopek in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze |
| PL217743B1 (pl) * | 2004-05-15 | 2014-08-29 | Vertex Pharma | Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw |
| JP5001150B2 (ja) * | 2004-06-08 | 2012-08-15 | ファミリーズ オブ スパイナル マスキュラー アトロフィー | 脊髄性筋萎縮症のための２，４−ジアミノキナゾリン |
| AU2005272627A1 (en) * | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| PT1796660T (pt) * | 2004-09-17 | 2017-02-13 | Biomas Ltd | Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta |
| ES2380632T3 (es) * | 2004-11-24 | 2012-05-17 | Vertex Pharmceuticals Incorporated | Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas |
| WO2006074223A2 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof |
| US8987306B2 (en) * | 2005-06-07 | 2015-03-24 | The Trustees Of The University Of Pennsylvania | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold |
| EP1898940A4 (en) * | 2005-06-07 | 2010-05-26 | Univ Pennsylvania | Alpha2beta1 / GPIa IIA INTEGRIN INHIBITORS |
| CN101268084A (zh) * | 2005-07-28 | 2008-09-17 | 沃泰克斯药物股份有限公司 | 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物 |
| WO2007027742A2 (en) * | 2005-08-31 | 2007-03-08 | The Trustees Of The University Of Pennsylvania | SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS |
| US7985755B2 (en) | 2006-08-01 | 2011-07-26 | Families Of Spinal Muscular Atrophy | 2,4-diaminoquinazolines for spinal muscular atrophy |
| WO2008033757A2 (en) * | 2006-09-11 | 2008-03-20 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives |
| US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
| US20080160081A1 (en) * | 2006-12-11 | 2008-07-03 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making, and methods of use |
| FR2923160B1 (fr) * | 2007-11-02 | 2013-07-26 | Pasteur Institut | Composes destines a prevenir ou traiter une infection virale. |
| EP2635907A4 (en) | 2010-11-05 | 2014-04-16 | Univ Brandeis | ICE-COLDED ALPHA SYNNUCLEINE A BIOMARKERS |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| JP6193888B2 (ja) | 2012-01-26 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| RU2016148364A (ru) | 2014-05-12 | 2018-06-13 | Конатус Фармасьютикалз, Инк. | Лечение осложнений хронического заболевания печени |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| JP2019500397A (ja) | 2015-12-31 | 2019-01-10 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | カスパーゼ阻害剤を肝疾患の治療に使用する方法 |
| JP2019530696A (ja) | 2016-10-05 | 2019-10-24 | ノバルティス アーゲー | 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物 |
| EP3935042B1 (en) * | 2019-03-07 | 2024-08-28 | NOBO Medicine Inc. | Caspase inhibitors and methods of use thereof |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
| KR102670554B1 (ko) * | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| DD232699A1 (de) | 1983-11-18 | 1986-02-05 | Adw Ddr | Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern |
| FR2582514B1 (fr) | 1985-05-30 | 1988-02-19 | Rhone Poulenc Sante | Medicaments a base d'amides, nouveaux amides et leur preparation |
| US5714484A (en) | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| US6063794A (en) | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
| KR20000049048A (ko) | 1996-10-11 | 2000-07-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인터루킨-1β 전환 효소의 아스파르테이트 에스테르 억제제 |
| PL332640A1 (en) | 1996-10-11 | 1999-09-27 | Warner Lambert Co | Sulphonamide-group substituted derivatives of aspartic acid as inhibitors of an interleukin-1beta transforming enzyme |
| WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| TR200201920T2 (tr) | 1999-05-07 | 2002-09-23 | Texas Biotechnology Corporation | İntegrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri. |
| WO2000068188A1 (en) | 1999-05-07 | 2000-11-16 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| AR026748A1 (es) * | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| ES2295171T3 (es) | 2000-06-07 | 2008-04-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de caspasa y sus usos. |
| JP2005509028A (ja) | 2001-10-09 | 2005-04-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法 |
| EP1485107A1 (en) | 2002-02-11 | 2004-12-15 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| WO2003088917A2 (en) | 2002-04-19 | 2003-10-30 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| MXPA05000069A (es) | 2002-06-28 | 2005-04-11 | Vertex Pharma | Inhibidores de caspasa y uso de los mismos. |
| US7612091B2 (en) | 2002-12-20 | 2009-11-03 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| ES2380632T3 (es) | 2004-11-24 | 2012-05-17 | Vertex Pharmceuticals Incorporated | Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas |
-
2003
- 2003-06-27 MX MXPA05000069A patent/MXPA05000069A/es unknown
- 2003-06-27 RU RU2005102094/04A patent/RU2005102094A/ru unknown
- 2003-06-27 NZ NZ537807A patent/NZ537807A/en unknown
- 2003-06-27 PE PE2003000653A patent/PE20040728A1/es not_active Application Discontinuation
- 2003-06-27 KR KR10-2004-7021300A patent/KR20050013260A/ko not_active Ceased
- 2003-06-27 IL IL16598603A patent/IL165986A0/xx unknown
- 2003-06-27 AU AU2003248758A patent/AU2003248758A1/en not_active Abandoned
- 2003-06-27 US US10/609,147 patent/US7553852B2/en not_active Expired - Fee Related
- 2003-06-27 TW TW092117681A patent/TW200404783A/zh unknown
- 2003-06-27 AR ARP030102352A patent/AR040350A1/es unknown
- 2003-06-27 EP EP03762231A patent/EP1539701A1/en not_active Withdrawn
- 2003-06-27 CN CNB038187930A patent/CN100503572C/zh not_active Expired - Fee Related
- 2003-06-27 CA CA002493646A patent/CA2493646A1/en not_active Abandoned
- 2003-06-27 BR BR0312232-8A patent/BR0312232A/pt not_active IP Right Cessation
- 2003-06-27 JP JP2004518103A patent/JP4616643B2/ja not_active Expired - Fee Related
- 2003-06-27 PL PL03374598A patent/PL374598A1/xx not_active Application Discontinuation
- 2003-06-27 WO PCT/US2003/020557 patent/WO2004002961A1/en not_active Ceased
- 2003-06-30 UY UY27872A patent/UY27872A1/es unknown
-
2005
- 2005-02-17 NO NO20050851A patent/NO20050851L/no not_active Application Discontinuation
-
2009
- 2009-05-12 US US12/464,380 patent/US8129381B2/en not_active Expired - Fee Related
-
2010
- 2010-02-04 JP JP2010023632A patent/JP2010143942A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US7553852B2 (en) | 2009-06-30 |
| US20090281128A1 (en) | 2009-11-12 |
| KR20050013260A (ko) | 2005-02-03 |
| EP1539701A1 (en) | 2005-06-15 |
| JP2010143942A (ja) | 2010-07-01 |
| TW200404783A (en) | 2004-04-01 |
| CA2493646A1 (en) | 2004-01-08 |
| PE20040728A1 (es) | 2004-10-23 |
| JP4616643B2 (ja) | 2011-01-19 |
| RU2005102094A (ru) | 2006-02-27 |
| US8129381B2 (en) | 2012-03-06 |
| WO2004002961A1 (en) | 2004-01-08 |
| PL374598A1 (en) | 2005-10-31 |
| IL165986A0 (en) | 2006-01-15 |
| JP2005533825A (ja) | 2005-11-10 |
| AU2003248758A1 (en) | 2004-01-19 |
| BR0312232A (pt) | 2005-05-10 |
| UY27872A1 (es) | 2003-12-31 |
| NZ537807A (en) | 2007-05-31 |
| NO20050851L (no) | 2005-03-29 |
| CN1675184A (zh) | 2005-09-28 |
| US20040072850A1 (en) | 2004-04-15 |
| MXPA05000069A (es) | 2005-04-11 |
| CN100503572C (zh) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040350A1 (es) | Inhibidores de caspasa y usos de los mismos | |
| JP2005533825A5 (enExample) | ||
| JP2003535865A5 (enExample) | ||
| CA2583022A1 (en) | Acetamide compounds as fungicides | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| AR067896A1 (es) | Procedimiento para sintetizar compuestos utiles para tratar hepatitis c | |
| ME02221B (me) | Postupak za proizvodnju intermedijara jedinjenja korisnih kao modulatori opioidnih receptora | |
| JP2018511647A5 (enExample) | ||
| JP2003534325A5 (enExample) | ||
| PH12012502363A1 (en) | Process for the preparation of dihydropyrrole derivatives | |
| RU2005140657A (ru) | Ингибиторы каспаз и их применение | |
| IL278757A (en) | Method for Preparation (3R, 4S) –3– Acetamido – 4 – Idyl– N– (Tert-Butyl) Pyrolidine – 3 – Carboxamide | |
| JP2006513220A5 (enExample) | ||
| FI3781562T3 (fi) | P300:n ja/tai cbp:n modulaattorien valmistusmenetelmä | |
| UA86013C2 (ru) | Производные арилалкилкарбаматов, их получение и применение в лечении | |
| ATE381554T1 (de) | Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen | |
| TN2011000308A1 (fr) | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique | |
| MXPA04002653A (es) | Metodo para preparar compuestos de pirimidinona y sales farmaceuticamente aceptables del mismo. | |
| WO2009044803A1 (ja) | 不斉触媒マイケル反応生成物の製造方法 | |
| JP2007525503A5 (enExample) | ||
| RU2006134258A (ru) | Ингибиторы каспаз и их применение | |
| TW200510366A (en) | 1, 2, 4-trioxepanes as precursors for lactones | |
| DE112007001452A5 (de) | Verfahren zur Herstellung von wasserstoffreichen Cyclosiloxanen | |
| EA201170899A1 (ru) | Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif | |
| WO2021016220A3 (en) | Synthesis of substituted furans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |